Maxim Group Reinstates VNRX with a 'Buy' Rating and $4 Target
Maxim Group reinstated its 'buy' rating on VNRX with a $4 price target, a 179.72% upside from the current price.
Key Points
- Maxim Group reinstated its 'buy' rating on VNRX with a $4 price target on June 18, 2026.
- Maxim Group's $4 price target implies 179.72% upside from VolitionRx Limited's ($VNRX) current $1.43 share price.
- VNRX shares traded around $1.43, with recent insider sales by company executives.
- Institutional investors like Lagoda Investment Management reduced their holdings significantly.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Maxim Group has reinstated its coverage of VNRX with a 'buy' rating and set a price target of $4, according to analyst Michael Okunewitch. This announcement was made on June 18, 2026, and comes as the stock trades around $1.43.
Other Institutional Activity in VNRX
Several institutional investors have recently adjusted their positions in VNRX. Lagoda Investment Management, L.P. significantly reduced its stake by 10,656,153 shares, ending with 807,450 shares valued at about $3.26 million. Meanwhile, Silverberg Bernstein Capital Management LLC slightly increased its holdings by 1,933 shares to 251,215 shares, worth approximately $50,745. Geode Capital Management, LLC also cut its position by 902,482 shares, leaving it with 61,504 shares valued at $248,510. Vanguard Capital Management LLC and Luminus Management LLC both established new positions, each holding 50,684 and 49,750 shares respectively.
VolitionRx Limited Stock Up 218.3%
VNRX shares are currently trading near $1.43. The stock has seen significant volatility as institutional investors adjust their positions and analysts update their ratings.
$VNRX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at VolitionRx Limited
Recent insider activity at VNRX includes several sales by company executives. On March 17, 2026, Nicholas Plummer, General Counsel at Volition Diagnostics, sold 7,003 shares at an average price of $0.19. Similarly, Chief Scientific Officer Jacob Vincent Micallef sold 5,310 shares at the same price. Secretary Rodney Gerard Rootsaert and Chief Commercial Officer Gael Forterre also sold shares on the same day.
Analysts Set New Price Targets
On June 18, 2026, Maxim Group reinstated its coverage of VNRX with a 'buy' rating and a $4 price target. This follows other recent analyst activity, such as HC Wainwright & Co. maintaining a 'buy' rating with a $1 target on April 2, 2026, and D. Boral Capital maintaining a 'buy' with a $3 target on March 31, 2026. The consensus among analysts remains positive with a 'buy' recommendation.
Bottom Line
The recent analyst activity and institutional changes reflect ongoing interest and adjustments in VNRX's stock, with Maxim Group's reinstated 'buy' rating and $4 target suggesting potential upside. Investors often track these updates for insights, though it's important to remember that 13F filings and analyst ratings are backward-looking and may not reflect current conditions.
Get VolitionRx Limited alerts
New 13F filings, insider trades, and analyst moves on $VNRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.